Short Interest in PAVmed Inc. (NASDAQ:PAVM) Declines By 50.2%
by Doug Wharley · The Cerbat GemPAVmed Inc. (NASDAQ:PAVM – Get Free Report) was the recipient of a large drop in short interest in February. As of February 27th, there was short interest totaling 49,462 shares, a drop of 50.2% from the February 12th total of 99,245 shares. Based on an average trading volume of 52,636 shares, the days-to-cover ratio is currently 0.9 days. Currently, 5.3% of the shares of the stock are short sold. Currently, 5.3% of the shares of the stock are short sold. Based on an average trading volume of 52,636 shares, the days-to-cover ratio is currently 0.9 days.
Institutional Trading of PAVmed
A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC lifted its position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) by 392.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the quarter. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.93% of the company’s stock.
Analyst Ratings Changes
Several analysts have recently commented on PAVM shares. Zacks Research lowered shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Wall Street Zen raised PAVmed to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Finally, Ascendiant Capital Markets cut their price target on PAVmed from $600.00 to $510.00 and set a “buy” rating for the company in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, PAVmed presently has a consensus rating of “Hold” and a consensus price target of $510.00.
Check Out Our Latest Stock Report on PAVM
PAVmed Stock Down 3.4%
Shares of NASDAQ:PAVM traded down $0.36 during trading on Thursday, reaching $10.38. The stock had a trading volume of 29,261 shares, compared to its average volume of 1,296,249. The stock has a market cap of $10.17 million, a P/E ratio of -0.61 and a beta of 0.90. The business has a fifty day moving average price of $9.28 and a 200-day moving average price of $11.03. PAVmed has a fifty-two week low of $6.00 and a fifty-two week high of $28.44.
About PAVmed
PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.
Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.